Domestic company won the case in the patent dispute of androgenetic alopecia remedy, Finasteride 1mg

On November 30th Judge Lee doo hyung, Suwon District Court 6^th division, gave a decision on this case that MSD Korea failed in Patent infringement prohibition lawsuit against Hanmi submitted on June 28^th 2006

Original product of Androgenetic alopecia remedy, Finasteride is MSD¡¯s Propecia. In March 2005 Hanmi instituted a lawsuit against MSD for Patent invalidity then the case was judged to be invalidity August this year.

Based on the Intellectual Property Tribunal¡¯s prior judge, Suwon District Court announced Hanmi¡¯s winning regarding production and Sale prohibition, which was domestic company¡¯s winning.

Hanmi¡¯s official said Suwon District Court¡¯s judge was that they cannot admit patent if the company simply restrict the dosage of Finasteride.

Besides Hanmi put ¡®Finated¡¯ that has a Finasteride component on the market as a first generic in December 2006 and progresses joint marketing with androgenetic alopecia remedy , ¡®Moxidil 5%¡¯ that has a Minoxidil component.

 androgenetic alopecia remedy, Finasteride 1mg¡¯s annual market size is 260 million won. As ¡®Finated¡¯¡¯s market share increases up to about 20% in the launching year, the market share of Propecia which is an original product fell to about 80%.

Young doctor¡¯s association of No won ku and Yoo Deok Ki(the director) got the 6^th Hanmi¡¯s true doctor prize.

Hanmi pharmaceutical company and doctor¡¯s association of Seoul had ceremony at Lotte hotel sapphire room at 7pm on 30^th to give a prize, 10 million won, and a medal to Young doctor¡¯s association of No won ku and Yoo Deok Ki(the director) who were chosen as the prize winners of this year.

Young doctor¡¯s association of No won ku which was established to help extremely poor people in the region in 2000 has contributed to establish medical sercive culture of sharing through volunteer work visiting welfare organization and supporting poor youths.

Yoo Deok Ki(the director) has helped neglected neighbors through medical volunteer work residing Dobong region since 1989 and especially he has done beauty culture volunteer work for helpless neighbors after he got a beauty culture license in 2004.

Lim Seon Min, the president of Hanmi, participated in the ceremony and said ¡°I give my honor to Yoo Deok Ki(the director) and Young doctor¡¯s association for their helping helpless neighbors with sincereness. Hanmi pharmaceutical company will take the responsibility of being a company for society to support true doctors.¡±

In the mean time, Hanmi¡¯s true doctor prize that is to let others know about good behavior of true doctors who have committed their life in a medical field to help neglected neighbors was offered by Hanmi pharmaceutical company and doctor¡¯s association of Seoul and it is the 6^th ceremony this year.

Arino is good for infants and children because it doesn¡¯t contain stimulating substance on skin. Arino has four types of the size.

Hanmi pharmaceutical company launched moist dressing band ¡°Arino¡± which is made of a hydrocolloid

Hanmi said Arino helps an injury to be cured rapidly minimizing a scar and repressing a scab formation that causes a scar by making a humid environment on an injured part.

Hanmi added that Arino reduces nerve stimulation occurring because of dryness on an injured part by maintaining exudates and reducing a pain through a rapid removal of an inflammation without applying an ointment or an antiseptic on an injured part.

Besides Hanmi emphasized that patients can decide easily when to change it since patients can observe an injured part or exudates without removing dressing because of its transparent type and Arino can protect an injured part from a virus and a dirt with a good permeability.

Hanmi also explained that Arino has as excellent adhesive power as patients can use it on curved parts of body such as wrist and knee and use it even when patients are taking a bath or swimming.             

Arino is being launched in various sizes; X-large (5 pieces), Large (6 pieces), Middle (8 pieces), Small (9 pieces) and an one piece of it can be used for 2~3days. Patients can use it by cutting it according to size of an injured part since an absorption part was manufactured to fit an adhesion part.

Hanmi pharmaceutical company fortified a functional ingredient and lowered the cost by launching a new product.

Hanmi pharmaceutical company launched a comprehensive cold remedy for a daytime and a night ¡°Suspen Day Night¡±.

¡°Suspen Day Night¡± which put together ¡°Suspen Day¡± and ¡°Suspen night¡± that were being sold separately is composed of 8 capsules for a daytime and 4 capsules for a night.

 It is divided into a white capsule that lessens drowsiness in a daytime and a blue capsule that lessens the symptoms of cold such as a pain through a sound sleep.

Suspen Day Night contains an acetaminophen 500mg in an each capsules and it can lessen the symptoms of cold and lower body temperature relieving a pain when it is taken three times (two capsules) a day, 1000mg for a dosage.

Hanmi¡¯s product manager said ¡°we launched a comprehensive cold remedy for a daytime and a night ¡°Suspen Day Night¡± that put together existing products. Hanmi fortified a functional character such as a prevention of drowsiness in a daytime and lowered the cost by putting together existing products so that patients don¡¯t feel economically burdened.

Sankei highlighted an economy cut of medical expenses on a special edition on last 16^th.

Sankei, the Japanese representative business newspaper, published a special edition about an obesity remedy ¡®Slimmer capsule¡¯ which Hanmi launched recently.

Focusing on will of developing obesity remedy (super generics) in Korea, Sankei reported that Hanmi got ahead of other pharmaceutical companies in this field on a special edition about ¡®metabolic syndrome¡¯ on last 16^th.

Sankei reported that Hanmi got item permission earlier than others and launched super generics whose additional salts had changed right after PMS of Reductyl capsule which is an appetite suppressing remedy of Abbott had been completed.

Especially Sankei explained in detail that Abbott sued Hanmi that developed Slimmer for being infringed on a patent but it was rejected.

And Sankei reported that the launch of super generics contributed to customer¡¯s economy cut of medical expenses and this phenomenon made other companies try to develop super generics explaining that Abbott¡¯s price sale followed after Hanmi¡¯s price policy that set the price of Slimmer half of Reductyl¡¯s.

Sankei reported about the movement for developing super generics in Korea quoting Chang An Soo¡¯s (CEO of Hanmi) speaking ¡°we are investing research budget not only on Anti-cancer medicine and bio generics but also on super generics¡±

In Japan, in the mean time, obesity remedy that has sibutramine component is not launched yet and Eisai is in the progress of the clinical test for the permission of Reductyl which is an original product at the moment.

Forbes put a high valuation on Hanmi for Paperless, Environment friendly, and Well-being management.

Hanmi pharmaceutical company got ¡°the 2007 Forbes management first prize¡± in Lohas management division.

Chang An Soo, CEO of Hanmi, participated in ¡®The 5th management first prize ceremony¡¯ which was held at Shilla Hotel Emerald hall at 10:30 am on September 5^th and got the first prize in Lohas management division.

Forbes put a high valuation on Hanmi because Hanmi adapted ¡®paperless¡¯ way utilizing computers and PDAs instead of documents by adapting ERP IT technology and took the social responsibility through Environmentally friendly management that tightens the safety by changing the medicine for children that had a single cap into double capped one with 30 hundred million won of investment.

Especially Hanmi got the high score for national wide Obesity extirpation campaign that Hanmi is planning and promoting based on ¡®Well-being¡± strategy to upgrade the quality of life of customers.

Chang Ann Soo, CEO of Hanmi, said ¡°Pharmaceutical companies need to take a responsibility for supporting society to help consumers live well in the cleaner environment. Hanmi set a goal for managing the company according to the Lohas which is an environmentally friendly life style.¡±

In the mean time, ¡°the 2007 Forbes management first prize¡± is being awarded to the companies that run business well in 6 departments including Lohas Business Prize that was established in 2003 by KSQM and Chung Ang Ilbo.

Samsung life insurance, GS retail, Lotte home shopping, Korean coinage public cooperation, Kyeong gi provincial office other than Hanmi pharmaceutical company got ¡°the 2007 Forbes management first prize¡± in Lohas management division

Hanmi goes in to global market with Facility investment as good as cGMP

 The plant can take charge of domestic and global entrusted production.

 Hanmi pharmaceutical company said they got KGMP approval from KFDA for building the Pyeong teak plant (Cepha plant) for the exclusive use of Cephalosporin Antibiotic on last 24^th.

The Cepha plant had been constructed from March 2006 to last January with an investment 370 hundred million won and equips pipe lines for injections tablet and Kapsel powder.

The pipe line can supply up to 70% of Cephalosporin Antibiotic that is being consumed domestically at the moment since it can establish more than two times of pipe lines for each kinds of product when it¡¯s necessary.

Cepha plant has an automatic system as good as cGMP which can perform air conditioning, water disposal, and electric power and it can monitor room temperature, humidity, pressure, particle, and wind velocity using Building Management System.

Moreover, it has former air method¡¯s facility (it can issue polluted air to the outside without circulation) that is required in developed countries and it can save energy adapting energy withdrawing system.

 Chang An soo, Hanmi¡¯s CEO, said ¡°Cephalosporin Antibiotic assumes massive proportions in Hanmi pharmaceutical company. When the plant begins to operate in earnest, Hanmi can supply finished Cephalosporin Antibiotic such as Triaxone, Tazime not to only Asian market such as South East Asia, China but also to Europe and Japan so that the globalization of Hanmi will be accelerated.¡±

In the mean time, Cephalosporin separation policy that makes the plant for for the exclusive use of Cephalosporin Antibiotic ready by 2010 to produce Cephalosporin Antibiotic domestically has become institutionalized. However when all the domestic pharmaceutical companies that is producing and selling Cephalosporin Antibiotic at the moment try to equip the separated production facility, national waste of surplus and overlapped invest on facilities is expected.

Hanmi pharmaceutical company is considering an entrusted production for pharmaceutical companies that feel burdened by invest on separated Cephalosporin Antibiotic production facilities. In addition, Hanmi is anticipating a big increase of global sales considering the fact that developed countries such as America, Japan and Europe are already considering OEM with Hanmi.

Pyeong Teak industrial complex where Cepha plant is located in is an industrial complex whose size is 36000m². Bio plant and administration center was already constructed in addition to Cepha plant whose size is 18,000m². Besides Hanmi has a plan to build a plant for anti-cancer medicine in the future, which will lead Hanmi to prospective company that produces brand new superior medicine.

The clinical book contains results of pre-clinical test, the first, second, and third clinical test which were collected for 5 years.

It will be criteria to prove efficacy and safety of Slmmer

Hanmi pharmaceutical company reported that they published a clinical book of an obesity remedy Slimmer recently.

Slimmer is the world¡¯s first obesity remedy that has methyl acid salt on sibutramine and Hanmi got sales permission from KFDA on July 2^nd.

Hanmi said ¡°Slimmer is the only product that went through pre-clinical test, the first, second, and third clinical test like a new medicine among obesity remedies (super generics) in Korea. We published clinical book to show that the efficacy and safety of Slimmer are differentiated from other products apparently.

Hanmi has invested 42 hundred million won for R&D for 5 years and the clinical book contains clinical results of pre-clinical tests for single medication of toxic, repeated medication of toxic, genetic toxic, toxic of reproduction, cancer, efficacy, general medicine, absorption, distribution, metabolism, excretion and of the first, second, third clinical tests that have been collected for 5 years.

Hanmi said ¡°The clinical book contains the result of the third clinical test of Slimmer that was done by Choi Woong Hwan(Hanyang university), Kim Kyeong Soo(Catholic university), Park Hye Sonn(Seoul Asan Hospital), Lee Kwan Woo(Aju university), Kim Beom Teak(Aju university), An Cheol Woo(Yeong Dong Severance Hospital). The clinical book will be criteria to prove efficacy and safety of Slmmer.¡±

The third clinical test of Slimmer which had been done to 200 obesity patients in 5 hospitals from July 2004 showed that patient had lost weight more than 6%, 5cm waist girth, 3.8% of heap girth, 1.9kg/m² BMI and especially lipid & LDL cholesterol whereas HDL cholesterol which is healthful had increased

In the mean time, the safety and efficacy of Slimmer were proved as the result of clinical test of Slimmer was inserted in Human & Experimental Toxicology (2005.2) and Clinical Therapeutics (2004. 12) which are SCI theses published in USA.

Hanmi pharmaceutical company has kept doing social contribution activities focusing on restoring Hanmi¡¯s profit into ¡®improving the quality of people¡¯s life¡¯ and development o medicine. Various campaigns such as ¡°Blood donation,¡± ¡°Hanmi¡¯s true doctor prize¡±, ¡°and medicine support for children in North Korea represent it.

-Culture division-

*Improvement of the quality of people¡¯s life through building a common good foundation.

In 2002, Hanmi established Hanmi culture foundation to realize ideology that restoring Hanmi¡¯s profit to society and improving the quality of people¡¯s life in a cultural way and in January 2003 opened Hanmi gallery.

Hanmi gallery, the Korean first photo gallery authorized by government, has contributed to development of Korean photo culture with supporting photographers¡¯ activities, discovering photos, and publishing books.

Hanmi gallery has exhibition of the work of Korean photographers who have unique insight every two months for free. It is easy to get there because it is located at Hanmi tower 19^th floor nearby Olympic park.

Hanmi gallery was acknowledged as a representative gallery of Korea as it was chosen as one of the culture program of 2004 Seoul ICOM:The International Council of Museums that was held from October 2^nd to 8^th in 2004 for its speciality.

-Social welfare division-

*Blood donation & visiting Kkot dong nea (a village for helpless people) in Um seong.

Hanmi pharmaceutical company is the only company that has been doing ¡°Blood donation¡± as an annual campaign for 27 years from 1981.

Hanmi has been doing ¡°Blood donation¡± event with every employees after the New Year¡¯s ceremony every year and more employees are participating in the event as time goes by. ¡°Blood Donation¡± in which not only the head office but also affiliates participate has been continued as Hanmi¡¯s unique campaign that realizes company¡¯s ideology ¡°respect for life¡± and practices loving neighbors.

Besides, new employees visited Kkot dong nea and did a volunteer work for helpless old people and disables for 2 days.

*Women¡¯s volunteer club ¡®Cheong lok hoi¡¯ in Hanmi

Since it was established in 1980, ¡®Cheong lok hoi¡¯ in Hanmi¡¯ has been helping helpless people by opening one-day café and bazaar every year.

It has been doing charity activities like donating revenue that was collected by every woman employees for one day to an old people's home and to an orphanage.

And members of ¡®Cheong lok hoi¡¯ visit Seonglowon home for babies and do volunteer work there once in a month. Sometime ¡®Cheong lok hoi¡¯ gives Seonglowon the necessaries of life such as diapers, fans, detergents using money that was earned from one-day café and bazaar.

* Helping children in North Korea

Hanmi pharmaceutical company has helped children in North Korea. Hanmi has been supplying medicines to North Korea through social organizations such as Korean medicine association and Korean doctor¡¯s association with start of donating medicines and nutrients for children to North Korea through the medicine supplying headquarters for children in 1997. Hanmi will keep medicine supporting activities for children in North Korea.

*Helping a hopeless case

Hanmi pharmaceutical company donated one hundred million won to association for a hopeless case to help a hopeless case in August 2005 and has been continuing support after that.

-Education and learning division-

*Supply activities for medical industry

Hanmi pharmaceutical company has done positive supply activities to seminars, medical schools, hospitals, and medical research centers for growth of medical industry. Hanmi offered 2 medical prizes to them in 2001 and 2002.

In 2001, Hanmi offered ¡°Hanmi literature prize¡± which is for the literature about feelings doctors have toward patients to recover trust between doctors and patients.

The literatures is full of stories telling about human¡¯s love not about ¡°doctors¡± and it is getting more popular year by year.

In 2002, Hanmi offered ¡°Hanmi¡¯s true doctor prize¡± in partnership with Seoul doctor¡¯s association. This prize has been being offered to doctors who dedicate himself to medical industry with sincereness and make a better society through volunteer works for helpless people.

Hanmi also endeavors to support Korean medicine association, medical school, and drug prevention center and has been filling the role of ¡°respect for life¡± which is a motto of pharmaceutical companies by supporting medicines to a disaster area and to medication for free.

In 2006, Hanmi contributed to the development of small hospitals by offering ¡°Hanmi volunteers prize¡± in partnership with Small hospitals association.

Hanmi pharmaceutical company has been carrying out nationalwide diet campaign from July 2007 and participating in marketing and public relations of an obesity remedy ¡°Slimmer¡±

Hanmi pharmaceutical company leads the nationalwide diet project.

Hanmi said that they chose actress Kim Hee Ae as a representative in public relations of diet campaign which is a part of nationalwide diet project on last 5^th.

Kim Hee Ae who performed enthusiastically in SBS drama ¡°my husband¡¯s woman¡± which was finished recently and gained people¡¯s heart was nominated as a representative in public relations of diet campaign at the ceremony where Hanmi¡¯s high officers including Chairman Lim Seong Ki got together on last June 30^th.

Kim Hee Ae is going to participate in public relations and marketing event of diet campaign related to Hanmi¡¯s Slimmer and lead nationalwide diet campaign which is supported by Hanmi from July.

Kim Hee Ae started an official work as a representative in public relations of diet campaign as she participated in an opening ceremony of an obesity remedy Slimmer which was held in Cheon An and Mokwon on last 4^th.

Hanmi explained ¡°we chose Kim Hee Ae as a representative in public relations of diet campaign because she has been keeping her body in good shape through an exercise and alimentotherapy even though she is at the age of 40. Especially Kim Hee Ae will be the trademark of ¡°Hanmi Diet campaign¡± that notifies people of the danger of obesity that causes various diseases then extirpates it. She will play an active part in advertisement of a medical congress, website relate to obesity, medical magazines, and also of the campaign and posters of Slimmer.¡±  

Kim Hee Ae said ¡°I hope this event will help obesity patients to alleviate their anxiety.¡±

In the mean time, Hanmi has started to work out a marketing strategy as they launch an obesity remedy ¡°Slimmer¡± in July for the first time in Korea.

Hanmi has a plan to support Slimmer to be a key product succeeding hypertension remedy ¡°Amodipin¡± which is a representative product of Hanmi.

Hanmi pharmaceutical company got sales permission of Slimmer from KFDA on July 2nd, which allows Hanmi to launch Slimmer right away.

42 hundred million won has been invested on R&D for 5 years and also Hanmi has been supported by Ministry of Commerce, Industry and Energy for Slimmer¡¯s project. Hanmi anticipates safe & inexpensive diet

█ Hanmi launched Slimmer

A homemade obesity remedy (super generics) is launched for the first time.

Hanmi pharmaceutical company reported they got sales permission of an obesity remedy Slimmer which was developed in Hanmi¡¯s own name from KFDA on July 2nd

It is the first time for a domestic pharmaceutical company (Hanmi) to develop and sale obesity remedy super generics Slimmer and Hanmi can launch Slimmer right after getting permission.

Slimmer is the world¡¯s first obesity remedy super generics that attached methyl acid salt on sibutramine.

Hanmi has invested 42 hundred million won on R&D for 5 years and also Hanmi has been supported by Ministry of Commerce, Industry and Energy for being chosen as ATC project since 2003.

Hanmi went through a pre-clinical test in 2003, the first clinical test in April 2004, the third clinical test in December 2004, and an additional clinical toxic test in March 2006 like a new medicine to develop Slimmer

While Hanmi develops Slimmer and gets permission of it for several years, Hanmi made a law court look over the laws related to reexamination and super generics after discussing the rights and wrongs of trade pressure of America.

Hanmi said While super generics go through some parts of pre-clinical test and the first clinical test generally, Slimmer proved its efficacy and safety by conducting pre-clinical test and the first, the third clinical tests like a new medicine. Doctors who conducted clinical tests are sure about the success of Slimmer in the market since they appreciate the superiority of safety and efficacy.

█ Hanmi conducted pre-clinical test and the first, the third clinical tests like a new medicine

Hanmi proved Slimmer¡¯s superior efficacy by conducting the first and the third clinical tests and proved its safety by conducting every pre-clinical tests such as tests for single medication of toxic, repeated medication of toxic, genetic toxic, toxic of reproduction, cancer, etc. like a new drug even though Slimmer is just super generics.

Hanmi said they have increased Slimmer¡¯s degree of solution to water drastically by changing hydrochloric acid salt into methyl acid salt and Slimmer has superior tolerance to medicine than existing products.

The third clinical test of Slimmer which had been done to 200 obesity patients in 5 hospitals from July 2004 showed that patient had lost weight more than 6%, 5cm waist girth, 3.8% of heap girth, 1.9kg/m2 BMI and especially lipid & LDL cholesterol whereas HDL cholesterol which is healthful had increased

The safety and efficacy of Slimmer were proved as the result of clinical test of Slimmer was inserted in Human & Experimental Toxicology (2005.2) and Clinical Therapeutics (2004. 12) which are SCI theses published in USA.

█ Slimmer is expected to be a global super generic product.

Slimmer is in the progress of patent judgment in 50 countries after Hanmi filed an application with the Patent Office for a patent of Slimmer in October 2002 for the first time and now Hanmi got patent for Slimmer in 6 countries including Korea, USA, Australia.

Hanmi showed confidence in Slimmer saying Hanmi is enthusiastically working on planning to register products in global market and sell Slimmer in Korea together. Slimmer is going to be recorded as the first instance of globalization that makes it possible for Hanmi to export their homemade super generics to the world.

█ Slimmer lessens obesity patients¡¯ medicine costs.

Hanmi said Slimmer can lessens obesity patients¡¯ medicine costs because it is 40~50% cheaper than existing products that cost about one hundred thousand won a month.

Slimmer is an ETC that needs a doctor¡¯s prescription and one dose of it needs to be taken a day regardless of meals.

█ Hanmi gained its case of patent dispute against Abbott, which proved Hanmi¡¯s technical superiority.

 It is reported that Hanmi gained its case of patent dispute against Abbott selling Reductyl, which proved Slimmer¡¯s technical superiority.

Hanmi pharmaceutical company gained its case of trial to confirm the scope of right and trial not to confirm the scope of right related to sibutramine mesilate which is a Slimmer¡¯s ingredient.

Hanmi said in December 2006 they won a lawsuit of forbidding patent infringement which had been instituted from July 2005 then they proved the superiority of technology and they also resolved every problems caused by the patent.

Sibtramine mesilate is registered in Chemical Abstarct Service which is a branch of America chemical association as a new material.

In the meantime, Hanmi plans to open obesity information site www.slimmer.co.kr that contains information about obesity for the public as they launch an obesity remedy Slimmer.

Syrup remedy (super generics) for alleviating fever for children is expecting over 100 hundred million dollar sales for the first launching year.

 Hanmi pharmaceutical company that produced eminent achievements in homemade super generics recording 483 hundred million won sales in three years after launching High blood-pressure remedy ¡®Amodipin¡¯ is expecting the second ¡®Amodipin¡¯¡¯s eminent achievements from Syrup remedy (super generics) for alleviating fever for children ¡®Maxibufen¡¯

Maxibufen is the world¡¯s first syrup remedy (super generics) containing dexibuprofen component for alleviating fever for children that was launched by Hanmi pharmaceutical company in December 2006 and it is a super generic that has been developed with 23 hundred million R&D support for five years.

This product can reduce side effect on venomousness and it can have an equal effect on body even when taken in just half of normal dosage of existing product by extracting Ibuprofen¡¯s active substances.

Hanmi said ¡°Maxibufen is a technically superior syrup remedy (super generics) for alleviating fever for children that has a Dexibuprofen component. Maxibufen is going to be the second growth power of Hanmi pharmaceutical company following Amodipin since Hanmi is considering not only its domestic sales but also exporting it to global market.

Maxibufen¡¯s sales are in a rising trend from 2 hundred million won in a month early in the year to 6~7 hundred million won at the moment.

Hanmi said ¡°Accumulated sales of Maxibufen are up to 30 hundred million won. Hanmi will be able to achieve more than 100 hundred million sales for the first launch year because its sales are in a rising trend.¡±

Hanmi analyzed the main reason of sales¡¯s increase that Hanmi has technical superiority of the product and differentiates itself from other products by adapting a standard small 50ml container.

Maxibufen acknowledged by KFDA for its technical superiority was designated as a product of new medicine reexamination last November. And Hanmi proved its safety and efficacy by performing clinical test on children for the first time among the domestic syrup remedy for alleviating fever.

Hanmi is planning an export to global market letting difference of remedy type, the world¡¯s first Dexibuprofen syrup remedy, lead and already made an application not to only to the Korean government but also to 50 countries all over the world for a patent to accomplish it.

This product is available to children from 6 month old to 12 years old.

Hanmi will continue to lead other pharmaceutical companies to get ¡®transparent businesses¡¯ settled.

Hanmi announced that they gained distinction, ¡®a bronze tower industry medal ¡®, for being chosen as an exemplary tax paying company at COEX convention center on the 41st taxpayer